Results 71 to 80 of about 51,957 (233)
Revista Colombiana de Cardiología, 2010 ANTECEDENTES: la evidencia disponible de stents liberadores de medicamento proviene de estudios controlados con estrictos criterios de inclusión, limitando sus conclusiones y haciendo difícil la aplicación de sus resultados en el mundo real.
Bernardo Lombo +7 more
doaj
Examination of the coatings of coronary stents [PDF]
, 2006 In our study the main properties of coated coronary stents are shown, such as foreshortening, recoil, surface features and failures and the expansion properties. The types and the effects of active and passive coatings are introduced.
Bognár, Eszter +3 more
core
Role of noncoding RNA in vascular remodelling [PDF]
, 2016 Purpose of review: Noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) are becoming fundamentally important in the pathophysiology relating to injury-induced vascular remodelling.
Baker, Andrew H. +2 more
core +1 more source
COMPARISON OF A NOVEL BIODEGRADABLE STENT MAGMARIS WITH DRUG ELUTING RESOLUTE ONYX STENT: SAFETY AND 12 MONTH OUTCOMES [PDF]
, 2023 К.С. Алимбаев +4 more
openalex +1 more source
Actual problems of stenting using in critical limb ischemia (cli) treatment
Ендоваскулярна нейрорентгенохірургія, 2017 Critical limb ischemia is a life-threatening disease that often results in partial disability or death. One of the ways in optimizing its endovascular treatment is the stents using.
O.L. Nikishin +4 more
doaj +1 more source
On the role of specific drug binding in modelling arterial eluting stents [PDF]
, 2016 In this paper we consider drug binding in the arterial wall following delivery by a drug-eluting stent. Whilst it is now generally accepted that a non-linear saturable reversible binding model is required to properly describe the binding process, the ...
AR Tzafriri +13 more
core +1 more source
Use of bioresorbable vascular scaffold : a meta-analysis of patients with coronary artery disease [PDF]
, 2016 BACKGROUND: Differences in outcomes between bioresorbable vascular scaffold (BVS) systems and drug-eluting metal stents (DES) have not been fully evaluated.
Akhtar, Zaki +7 more
core +2 more sources
Coronary Artery Disease, 2019 Approximately, 10-20% of patients with drug eluting stent (DES) in-stent restenosis (ISR) will develop recurrent ISR; yet, the optimal management of recurrent DES-ISR is unknown. We sought to compare the outcomes of recurrent DES-ISR treated with drug eluting balloons (DEB) to those with repeated implantation of new-generation DES.A total of 172 ...
Wang, Guozhong +5 more
openaire +3 more sources
Development of coronary stents using advanced results of materials science and technology [PDF]
, 2004 Stents are high tech endovascular implants. K&M Inc. is the single Eastern European stent producer company. The market needs more biocompatible devices as the trend of the stent development all the producers have to react.
Dobránszky, János +3 more
core
Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI [PDF]
, 2017 BACKGROUND: Coronary revascularization guided by fractional flow reserve (FFR) is associated with better patient outcomes after the procedure than revascularization guided by angiography alone.
Al-Lamee, R +6 more
core +1 more source